NO880141L - IMPROVED FIBRINOLYTIC MIXING. - Google Patents
IMPROVED FIBRINOLYTIC MIXING.Info
- Publication number
- NO880141L NO880141L NO880141A NO880141A NO880141L NO 880141 L NO880141 L NO 880141L NO 880141 A NO880141 A NO 880141A NO 880141 A NO880141 A NO 880141A NO 880141 L NO880141 L NO 880141L
- Authority
- NO
- Norway
- Prior art keywords
- fibrinolytic
- cho
- composition
- enzyme
- mixing
- Prior art date
Links
- 239000003527 fibrinolytic agent Substances 0.000 title abstract 2
- 230000003480 fibrinolytic effect Effects 0.000 title abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 abstract 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 108010023197 Streptokinase Proteins 0.000 abstract 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007859 condensation product Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229960005202 streptokinase Drugs 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229960000187 tissue plasminogen activator Drugs 0.000 abstract 1
- 229960005356 urokinase Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
En blanding son effektivt oppleser blodklumper og reetable-. rer og oppretter blodstrømmen gjennom kransarterier eller andre blodkar hvor det har vært en trombose. Den fibrinolytiske blandingen ifølge foreliggende oppfinnelse består av et enzym, f.eks. streptokinase, urokinase, vevsplasminogenaktivator eller et annet fibrinolytisk enzym, og en overflateaktiv kopolymer. Sistnevnte kan vsre et etylenoksyd-propylenoksyd-kondensasjons-produkt med følgende generelle formel:. hvor a er et tall, slik at den hydrofobe delen representert ved (CH0), har en molekylvekt fra ca. 950 til 4000, fortrinnsvis fra 175til 4000, og b er et slikt tall at den hydrofile delen representert ved (CH0), utgjør fra ca. 50 til ca. 90 vekt% av forbindelsen.A composition that effectively dissolves blood clots and reestablishes and restores blood flow through coronary arteries or other blood vessels where there has been thrombosis. The fibrinolytic composition of the present invention consists of an enzyme, e.g. streptokinase, urokinase, tissue plasminogen activator or other fibrinolytic enzyme, and a surfactant copolymer. The latter may be an ethylene oxide-propylene oxide condensation product of the following general formula:. where a is a number such that the hydrophobic portion represented by (CHO), has a molecular weight of from about 950 to about 4000, preferably from 175 to 4000, and b is such a number such that the hydrophilic portion represented by (CHO), constitutes from about 50 to about 90% by weight of the compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO922262A NO922262D0 (en) | 1986-05-15 | 1992-06-09 | IMPROVED FIBRINOLYTIC MIXING |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86358286A | 1986-05-15 | 1986-05-15 | |
| US4388887A | 1987-04-29 | 1987-04-29 | |
| US07/045,459 US4801452A (en) | 1986-05-15 | 1987-05-07 | Fibrinolytic composition |
| PCT/US1987/001067 WO1987006836A1 (en) | 1986-05-15 | 1987-05-08 | Fibrinolytic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO880141D0 NO880141D0 (en) | 1988-01-14 |
| NO880141L true NO880141L (en) | 1988-03-14 |
Family
ID=27488885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO880141A NO880141L (en) | 1986-05-15 | 1988-01-14 | IMPROVED FIBRINOLYTIC MIXING. |
Country Status (2)
| Country | Link |
|---|---|
| MC (1) | MC1856A1 (en) |
| NO (1) | NO880141L (en) |
-
1987
- 1987-05-08 MC MC87US8701067D patent/MC1856A1/en unknown
-
1988
- 1988-01-14 NO NO880141A patent/NO880141L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MC1856A1 (en) | 1988-12-19 |
| NO880141D0 (en) | 1988-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5084274A (en) | Inhibition of arterial thrombotic occlusion or thromboembolism | |
| ES2009264A6 (en) | PROCEDURE FOR OBTAINING AN IMPROVED FIBRINOLYTIC COMPOSITION. | |
| US4285932A (en) | Enzyme derivatives for use in the treatment of venous thrombosis | |
| Ambrus et al. | Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme | |
| Nilsson et al. | Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects | |
| DE3850531D1 (en) | Tissue plasminogen activator. | |
| Dosekun et al. | Ancrod in systemic lupus erythematosus with thrombosis: clinical and fibrinolysis effects | |
| DE69737500T2 (en) | Purified multimerase | |
| CA2194692A1 (en) | Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase | |
| Zamarron et al. | Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro | |
| JPH0753402A (en) | Virus-safe blood coagulation factor XIII preparation | |
| SE8301795L (en) | plasminogen activator | |
| CA2046632A1 (en) | Thrombolytic from vampire bat saliva | |
| EP0624642B1 (en) | Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament | |
| Markland | Fibrin (ogen) olytic enzymes from snake venoms | |
| ES2022934B3 (en) | ENZYMES MODIFIED WITH POLYURETHANE. | |
| KR100189698B1 (en) | Novel cdna of fibrinolytic serine protease | |
| KR0127776B1 (en) | CDNA sequences of novel proteases and proteins derived therefrom | |
| HUT59610A (en) | Process for producing pharmaceutical compositions for solving blood clot containing t-pa without glycosilyzing | |
| IE922400L (en) | Composition comprising an oxygen radical scavenger and a¹surface-active copolymer | |
| Konttinen | The effect of heparin on the fibrinolytic activity of streptokinase-activated human plasma | |
| Nguyen et al. | A thromboresistant surface by enzyme immobilization | |
| RU1838311C (en) | Method of synthesis of 2-(3-pyridyl)tetrahydrothiapyrane carbothioamide-2-oxide-1(1r,2r) | |
| Forbes et al. | Thrombolytic Therapy—Indications, Advantages and Disadvantages | |
| KR0173088B1 (en) | CDNA of novel thrombin-like protease |